-
Mashup Score: 5
Christie Ballantyne, MD, discusses new data from the ROSE2 trial examining the potential synergistic effects of obicetrapib with ezetimibe in high-intensity statin users.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 23Exploiting routine laboratory test to identify primary severe hypertriglyceridaemic patients in a large Italian hospital - 2 month(s) ago
Severe hypertriglyceridaemia (HTG), defined as plasma triglyceride (TG) concentrations greater than 10 mmol/L (885 mg/dL).1 Fasting TGs that are raised to this
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 27
Abstract. Hypertriglyceridemia (hTG) is associated with atherosclerotic cardiovascular disease, pancreatitis, and non-alcoholic fatty liver disease in large pop
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 52021 Dyslipidemia - Canadian Cardiovascular Society - 3 month(s) ago
Citation: Glen J Pearson, George Thanassoulis, Todd J Anderson, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021 Aug;37(8):1129-1150.
Source: ccs.caCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 32021 Dyslipidemia - Canadian Cardiovascular Society - 3 month(s) ago
Citation: Glen J Pearson, George Thanassoulis, Todd J Anderson, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021 Aug;37(8):1129-1150.
Source: ccs.caCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 0
Presented at AHA 2023, phase 1 data for lepodisiran showcased a 97% reduction in lipoprotein(a) levels at the 608 mg dose.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 8Inclisiran and cardiovascular events: a comprehensive... : Current Opinion in Cardiology - 6 month(s) ago
an significantly lowers LDL-C levels, as shown by phase III studies, by inhibiting hepatic synthesis of proprotein convertase subtilisin kexin 9 (PCSK-9), a protein implicated in the degradation of LDL receptors. Inclisiran has the benefit of subcutaneous injection twice a year, which may reduce patient nonadherence when compared with other LDL-C reducing therapies such as statins and ezetimibe, which require daily dosing. When added on top of statins, a greater proportion of patients achieved recommended cholesterol goals. It has also demonstrated a good safety profile with few adverse effects. Summary Inclisiran is a promising treatment for lowering LDL-C levels in people at high risk of atherosclerotic cardiovascular disease. It is a practical and well tolerated option for those who struggle to stick to medication regimes because of its twice-yearly dosage schedule and a good safety profile. Although it has been demonstrated to be effective in decreasing LDL-C, further research is n
Source: journals.lww.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 22023 Family Heart Global Summt - Family Heart Foundation - 7 month(s) ago
Our 2023 Family Heart Global Summit will be held in Washington D.C. on October 1 and 2. Join the conversation on FH and high Lp(a).
Source: familyheart.orgCategories: Cardiologists, Latest HeadlinesTweet-
.@NIH_NHLBI: October 1-2: Looking forward to joining #FHFoundation & colleagues at the 2023 Family Heart Global Summit. Theme is ""Through a Wider Lens: #Lipid Management Across #Populations and Lifetimes." #CVD #lipids #CASCADE #ImpSci #FindFH #KnowFH https://t.co/7cGuC0DsRs https://t.co/bPVAFnVjBl
-
-
Mashup Score: 2Redirecting immune, lipid, and metabolic drivers of early cardiovascular disease: the RESET cohort study and randomized trial - 7 month(s) ago
Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded programme that brings together a nationwide community of cardiov
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 7Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid - 7 month(s) ago
Patients with well-controlled LDL (low-density lipoprotein) levels still have residual cardiovascular risk associated with elevated triglycerides. Epidemiological studies have shown that elevated fas
Source: www.ahajournals.orgCategories: Cardiologists, Latest HeadlinesTweet
In this video, Christie Ballantyne, MD, discusses new data from the ROSE2 trial examining the potential synergistic effects of obicetrapib with ezetimibe in high-intensity statin users. https://t.co/56MlnzLEZL #Lipids